Mraz Lab

Very proud to share our new paper demonstrating that transformed follicular lymphoma has increased activity of CD40 signalling due to lower levels of miR-29. Evidence that the B-T cell interactions are important in tFL (Filip et al, Leukemia, 2026, rdcu.be/e4HwW).

In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. Full COBRRA trial results: nejm.org/doi/full/10.10…

FL therapy with tazemetostat is no more

👉👉Delighted to share our recent editorial on what is the meaning of Cure in the context of CLL. An important topic in the current era of excellent targeted therapy options @Hemasphere_EHA @UTMDAnderson pmc.ncbi.nlm.nih.gov/articles/PMC12…

🚨NEWS🚨 China’s NMPA approves pirtobrutinib for the treatment of R/R CLL/SLL following ≥1 line of systemic therapy including a BTKi, based on results from the phase III BRUIN CLL-321 study. Read more:bit.ly/4cRvsfW #lymsm #MedEd #MedNews

Very honored to give a keynote at the UK CLL forum 2026

ChEA-KG Human Transcription Factor Regulatory Network with a Knowledge Graph Interactive User Interface 1554 TFs >60k upregulated edges >60k downregulated edges >170k RummaGEO gene sets chea-kg.maayanlab.cloud @MaayanLab bioRxiv 2025 biorxiv.org/content/10.110…

#Hematology IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia #CLL #CLLsm #lymsm haematologica.org/article/view/1…

An update to the Hallmarks of Cancer framework for understanding (and researching) what causes human cancers. spkl.io/6010Aqwbi Douglas Hanahan @CellCellPress

@idibaps @hospitalclinic @FerranNadeu Cong

🆕Elías Campo rep una ajuda “Proof of Concept” del @‌ERC_Research #ERCPoC El projecte desenvoluparà una eina de diagnòstic precoç de la transformació de Richter, una evolució agressiva de la leucèmia limfàtica crònica #LLC 👉f.mtr.cool/orgmxqbecb

We got an ERC PoC grant today! our 2nd ERC grant :-) I would like to thank my colleague, Dr. Vasek Seda, for working so hard on developing this inhibitor: ceitec.cz/marek-mraz-z-c…

📣#ESHLCLL2026 PROGRAMME HIGHLIGHT: 3 MEET THE EXPERT SESSIONS by Jennifer Brown, Paolo Ghia, @HallekMichael! Join them on March 5-7 in Stockholm, Sweden for the 4th Translational Research Conference on Chronic Lymphocytic Leukaemia ➡ bit.ly/4cfagyf #ESHCONFERENCES

@Vedazije Předseda GAČRu by možná též poskytl dobrou perspektivu ... aspoň jako host.

Pamatujeme na doby, kdy se vedla diskuse o složení RVVI - mají tam být špičkoví vědci, nebo zástupci institucí? Podle našeho názoru RVVI potřebuje především lidi, kteří budou mít kapacitu se členství v Radě věnovat. Na druhou stranu je fajn vidět, že RVVI povstává z popela!

miRNA-223-3p downregulation in MKs decreases platelet production and enhances platelet procoagulant activity. TMEM16F messenger RNA is a target of miR-223-3p. Read in Blood Advances: ow.ly/MgXU50XWplz

2/ I got tired of doing this manually, so I built a Snakemake pipeline that handles the full workflow: → Download from GEO/SRA → QC and trimming → Align to hg38 (or any reference) → Peak calling → Generate normalized tracks github.com/crazyhottommy/…

Online Now: B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity dlvr.it/TQF1td

Our blueprint for a new precision ca paradigm. Customized combinations. Also how to give previously unstudied combinations safely without prior phase I trials. Higher degrees of matching correlate with improvement in all outcome parameters. Breaking new ground. ⛓️‍💥🎯🔥

Vyjádření GAČRu k tomu jak odcházející vláda sebrala peníze na vědu v roce 2025... trestuhodné a argumenty, že šlo o nějaké nevyčerpané peníze jsou liché: gacr.cz/informace-o-do…

This article suggests that cancer treatment contributes to mutagenesis: "More than 25% of driver mutations in normal tissue exposed to systemic anti-cancer therapy, including in TP53, could be attributed to treatment."

The 2025 ASH guidelines for older adults with AML are now out! An honor to contribute alongside leaders in the field and to represent patients and physicians from Latin America and other LMICs. I never imagined having the opportunity to be part of something like this! 🤯@ASH_hematology ashpublications.org/bloodadvances/…